Your search did not match any results.
Dear Customers and Partners,
I am excited to share that on October 17, 2018, Oracle announced that it entered into an agreement to acquire goBalto, which delivers leading cloud solutions to accelerate clinical trials by streamlining and automating the selection and set up of the best performing clinical research sites to conduct trials.
goBalto’s study startup solutions are activated at over 90,000 research sites across 2,000+ studies in over 80 countries to deliver significant savings to customers with over 30% quantifiable reduction in study startup cycle times. Clinical trial site selection and activation is one of the most manual and time consuming processes for our customers in the trial design phase and the addition of goBalto will remove another barrier from delivering treatments to patients faster.
Oracle Health Sciences already offers customers the industry's most advanced cloud solution for clinical trial planning, data collection, trial execution and safety management. goBalto adds the leading industry cloud solution that significantly reduces clinical trial startup time. Together, Oracle and goBalto will provide the most complete end-to-end cloud platform dedicated to unifying action and accelerating results for the Life Sciences industry.
We are thrilled to join forces with goBalto and welcome their team to Oracle’s Health Sciences Global Business Unit.
Oracle's industry organizations maintain unique domain knowledge, specialized expertise and focused product investments, which currently includes more than 22,000 Oracle employees and over $700 million in annual R&D spend. This model has proven highly successful across several industries, and we look forward to bringing these same benefits to the customers of goBalto.
For more information, please visit www.oracle.com/gobalto.
Thank you for your continued support.
Senior Vice President and General Manager
Oracle Health Sciences Global Business Unit
Oracle is currently reviewing the existing goBalto product roadmap and will be providing guidance to customers in accordance with Oracle’s standard product communication policies. Any resulting features and timing of release of such features as determined by Oracle’s review of the goBalto product roadmap are at the sole discretion of Oracle. All product roadmap information, whether communicated by goBalto or by Oracle, does not represent a commitment to deliver any material, code, or functionality, and should not be relied upon in making purchasing decisions. It is intended for information purposes only, and may not be incorporated into any contract.
Cautionary Statement Regarding Forward-Looking Statements
This document contains certain forward-looking statements about Oracle and goBalto, including statements that involve risks and uncertainties concerning Oracle’s proposed acquisition of goBalto, anticipated customer benefits and general business outlook. When used in this document, the words “anticipates”, “can”, “will”, “look forward to”, “expected” and similar expressions and any other statements that are not historical facts are intended to identify those assertions as forward-looking statements. Any such statement may be influenced by a variety of factors, many of which are beyond the control of Oracle or goBalto, that could cause actual outcomes and results to be materially different from those projected, described, expressed or implied in this document due to a number of risks and uncertainties. Potential risks and uncertainties include, among others, the possibility that the anticipated synergies of the combined companies may not be achieved after closing, the combined operations may not be successfully integrated in a timely manner, if at all, general economic conditions in regions in which either company does business may deteriorate and/or Oracle or goBalto may be adversely affected by other economic, business, and/or competitive factors. Accordingly, no assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what impact they will have on the results of operations or financial condition of Oracle or goBalto. You are cautioned to not place undue reliance on forward-looking statements, which speak only as of the date of this document. Neither Oracle nor goBalto is under any duty to update any of the information in this document.